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Abstract
This study investigated the effects of nicotine on memory and learning in adolescent and
adult male Fischer-344 rats. Rats were given 0.2 mg/kg/day of either nicotine or saline
chronically for 2 weeks and were tested in the Morris water maze as adolescents (Phase
1) and then again 4 months later as adults (Phase 2). There were 4 main groups:
nicotine/nicotine, nicotine/saline, saline/nicotine, and saline/saline. In Phase 2 rats were
tested for c-Fos and BrdU expression in the dentate gyrus of the hippocampus.
Behavioral data indicated that as adults, rats given nicotine were significantly improved
at the water maze task compared to rats given saline. Impairments of the S/N group
suggest performance in the maze is state dependent upon the nicotine. An increase in cFos expression was seen in the saline rats, and no BrdU expression was seen in either
group. The behavioral results imply that low doses of nicotine improve learning and
memory in adult rats. This provides support for studies investigating nicotine as a
therapeutic agent for diseases affecting cognition, such as Alzheimer’s.
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Just Say “Nootropic”: The Effects of Nicotine on Memory and Learning
in Adolescent and Adult Rats
For the past twenty years, nicotine and drugs that act as agonists to nicotinic
receptors have been under investigation due to their cognitive enhancing properties and
their potential for therapeutic use in certain neurodegenerative diseases, schizophrenia,
and attention deficit hyperactivity disorder (Dunbar et al., 2007; Levin & Rezvani, 2000;
Rezvani & Levin, 2001; White & Levin, 1999, , 2004). At the present time, the drugs
available to patients suffering from Alzheimer’s disease and other diseases affecting
cognition provide minimal relief of symptoms. Most of these drugs involve the indirect
stimulation of cholinergic receptors, however studies have shown that direct stimulation
of nicotinic receptors—via nicotine itself or nicotinic agonists—may have a more
pronounced therapeutic effect (Ono, Hasegawa, Yamada, & Naiki, 2002; Rezvani &
Levin, 2001). Thus, nicotine research has provided some promising results regarding
possible therapies for such diseases.
Nicotine: Neural Mechanisms
Nicotine, the main psychoactive ingredient found in tobacco, mimics the effects
of acetylcholine (ACh) at nicotinic ACh receptors (nAChRs). Like ACh, it modulates the
signaling pathways of target neurons by stimulating the release of several
neurotransmitters that are associated with memory, learning, and reward, including
acetylcholine, glutamate, dopamine, norepinephrine, and serotonin (Fagen, Mansvelder,
Keath, & McGehee, 2003; Levin, Limpuangthip, Rachakonda, & Peterson, 2006;
Mansvelder, van Aerde, Couey, & Brussaard, 2006; Rezvani & Levin, 2001; Wang et al.,
2008). It has been confirmed by multiple studies that nicotine has a pronounced effect on
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areas of the brain linked with reward, specifically the mesolimbic system, through the
increased release of dopamine (Clarke, 1992; Di Chiara, Acquas, Tanda, & Cadoni,
1992). This is the essence of the controversy surrounding nicotine as a therapeutic drug:
its stimulation of receptors that release reward-based neurotransmitters could lead to
addiction, particularly if the dose is high and self-administration is possible (Merlo Pich,
Chiamulera, & Carboni, 1999; Wang et al., 2008).
Despite this controversy, addiction studies of nicotine provide some important
information that leaves the door open for nicotine’s use in diseases affecting cognition.
The most common way people become addicted to nicotine is via cigarette smoking
(Winger, Woods, & Hofmann, 2004). However, when nicotine is introduced into the
body in this way, a large amount of nicotine reaches the brain extremely rapidly on
inhalation. The immediate, semi-euphoric effect that results is what increases the
likelihood for nicotine addiction (Winger et al., 2004). Additionally, studies involving
self-administration of nicotine in rats have shown that when rats are allowed to selfadminister, they take in doses of nicotine on par with that of a cigarette smoker, which
contributes to research labeling it as addictive (Abrous et al., 2002). Evidence suggests
that when nicotine is administered to animals (or humans) at a slow rate and in a
controlled manner (not through cigarettes or tobacco), the possibility for addiction is
much lower (Samaha, Yau, Yang, & Robinson, 2005). Thus, as long as the dose of
nicotine is low and patients are on a well-defined schedule, it is less likely to produce an
addiction and has the potential to be a safe therapeutic alternative.
Though nicotine is the main rewarding component in cigarettes and the reason
smoking can be addictive, it is important to understand that the harmful effects of
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smoking are largely due to the combination of an estimated 4000 constituents of cigarette
smoke—not the nicotine itself (Winger et al., 2004). When the smoke turns to vapor it
has high amounts of toxic carbon monoxide, which adds to the harmful effects of
cigarette smoking (Winger et al., 2004). Because of the toxic nature of the ingredients in
cigarettes and their reactions to being burned, it is no surprise that cigarette smoking can
lead to serious illnesses such as coronary heart disease, emphysema and various forms of
cancer (Winger et al., 2004). Nicotine alone, especially when administered intravenously
or by transdermal patches, does not cause these health problems (Winger et al., 2004).
The action of nicotine in the brain relies upon nAChRs. These receptors are
ligand-gated ion channels containing five subunits that form a circle around a central
pore, and allow the influx of positively charged ions. Subunits can be either alpha, beta,
gamma, or delta, but the subunits most connected to nicotinic involvement are alpha 4
beta 2 (α4β2) subunits or alpha 7 (α7) subunits (Hawi & Lowe, 2007; Winger et al.,
2004). When a nicotine molecule binds to a receptor, the receptor opens and allows
positively charged ions to enter. This leads to an excitatory postsynaptic potential
(EPSP), which increases the likelihood of neurotransmitter release from the responding
cell. It is this potential for neurotransmitter release that leads to nicotine’s cognitive
enhancing effects. The makeup of the subunits of the receptor as well as the location of
the receptor in the brain dictates the effect of the neurotransmitter release within the brain
(Winger et al., 2004).
Mouse studies of nicotine’s effect on gene expression and receptors have reported
that nicotine administration results in receptor upregulation in the nucleus accumbens
(one area from which nicotine is known to stimulate the release of dopamine), as well as
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in the hippocampus, which is highly involved in learning and memory (Wang et al.,
2008). Receptor upregulation is an increase in available receptors in the brain that can
occur in response to a large amount of drug present in that brain area. In order to provide
a place for the extra drug molecules to bind, receptors multiply—this results in an
increased effect of the drug, and also leads to the potential for withdrawal symptoms if
the drug is suddenly ceased. When receptors are exposed to a large amount a drug,
however, receptors can become desensitized and receptor downregulation can occur as a
compensatory mechanism (Benwell, Balfour, & Birrell, 1995).
With regard to nicotine’s action upon certain receptors, much promising data has
come from studies concerning nicotinic cholinergic receptors in rats and mice. The α7
and α4β2 receptors, in particular, have been demonstrated to play a role in cognitive
functioning (Levin, McClernon, & Rezvani, 2006). A study using α7- nAChR knockout
mice determined that mice missing these receptors performed poorly on attentional tasks
of cognitive function when compared to normal controls (Young et al., 2007).
Experiments performed with rats in a passive avoidance test also demonstrated that both
chronic and acute nicotine administration had cognitive-enhancing effects as a result of
α7-nAChR stimulation in the hippocampus (Uzum, Diler, Bahcekapili, Tasyurekli, &
Ziylan, 2004). Wild-type mice with α7-nAChRs have also demonstrated more cell
proliferation as a result of nicotine administration when compared to mice lacking these
receptors (Koike et al., 2004).
The Hippocampus
Multiple studies have shown that nicotine has a positive effect on memory and
learning in humans and non-human animals, and one of the areas of the brain most
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affected by nicotine administration is the hippocampus (Levin, Sledge, Baruah, & Addy,
2003; Wang et al., 2008). The hippocampus plays a key role in learning and memory,
particularly learning and memory involving spatial information (Izquierdo, 1995). Long
Term Potentiation (LTP) is the mechanism that allows for the hippocampus’ involvement
in memory storage and memory retrieval (Izquierdo, 1995). LTP is an increase in
synaptic effectiveness, which can result in changes in the synapses, an increase in
synaptic firing and an increase in neurotransmission in the hippocampus (Schumann et
al., 2004). Spatial learning tasks such as the Morris water maze can increase LTP in the
rat hippocampus, and it is possible that nicotine can also facilitate this process in
conjunction with these tasks.
One group has proposed that glutamate release in the hippocampus is enhanced by
nicotine. They examined the effect of nicotine and a glutamate agonist (dizocilpine) on
spatial learning in the radial arm maze. When the rats were given dizocilpine in
conjunction with nicotine, they displayed an impairment in working memory in the maze
(Levin et al., 2003). The dizocilpine was administered via a local infusion cannula in the
ventral hippocampus, so the impairment in working memory was localized specifically to
this brain area (Levin et al., 2003). This result provides support for the notion that the
hippocampus is an integral brain area in the formation of working memory, and that
glutamate neurotransmission as a result of nicotine administration is central to the
cognitive enhancing properties of nicotine.
Cognitive Enhancement in Humans
There have been numerous studies investigating nicotine’s effect on human
cognition. It has been shown that when regular smokers are deprived of cigarettes they
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experience withdrawal symptoms that include cognitive deficits, such as decreased
accuracy on tasks of performance, and a decrease in psychomotor skills (Hatsukami,
Fletcher, Morgan, Keenan, & Amble, 1989). One study demonstrated that as little as 24
hours after cigarette cessation, reaction times and errors related to vigilance tasks were
significantly increased (Hatsukami et al., 1989). Though it is possible that the cognitive
decline could have been due in part to the other symptoms of withdrawal from cigarettes
(including headaches, nausea, etc.), it is likely that the decline was at least partially a
result of the cessation of nicotine. In 24 hours the participants in the study were not
reported to have any other noticeable withdrawal symptoms, which supports the notion
that the removal of nicotine was a contributing factor to the decrease in performance on
the cognitive tasks.
Due to the potential for cognitive decline following nicotine cessation in cigarette
smokers, it is beneficial to investigate the effect of nicotine on adult non-smokers without
any attentional or cognitive deficits—this research demonstrates nicotine’s effectiveness
in improving cognition in normal, healthy controls. Non-smokers are an ideal baseline in
these types of studies because there is no possibility of withdrawal, which could skew the
results. Additionally, regular smokers would have to change their smoking patterns for
the study, which would introduce even more potential for variation in the results
(Hatsukami et al., 1989; Levin & Rezvani, 2000; Rezvani & Levin, 2001). Nicotine has
been shown to improve the attention of non-smoking normal controls when administered
through subcutaneous injections and transdermal nicotine patches, suggesting that it may
also have a similar effect on patients with attentional disorders or other cognitive
impairments (Levin, Conners et al., 1998; Levin & Rezvani, 2000).
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Alzheimer’s Disease
Because nicotine enhances the cognition of human non-smokers, it has been of
great interest to researchers whether it could have cognitive enhancing—and therefore
therapeutic—effects on people with various cognitive ailments, including Alzheimer’s
disease. Alzheimer’s disease (AD) is characterized by severe cognitive deficits,
including impairments of memory and executive (higher-order) function (Nixon, 2002).
Generally these deficits begin mildly, and become progressively worse as increased cell
death leads to severe cortical atrophy (Nixon, 2002). The most widely understood
neuropathology of post-mortem Alzheimer’s brains includes the presence of
neurofribrillary tangles and neuritic plaques (Buckner, Head, & Lustig, 2006; Nixon,
2002). The neuritic plaques are found largely in brain areas involved in learning and
memory, such as the neocortex, the hippocampus, and the amygdala. This provides
insight into Alzheimer’s negative effect on cognition as the disease progresses (Nixon,
2002).
In 2002, Ono and colleagues demonstrated that nicotine interferes with the
formation of in vitro amyloid plaques. This provides important information regarding the
neuroprotective effects of nicotine that extend beyond nicotinic receptor upregulation,
and supports the notion that nicotine can be used as a therapeutic agent in Alzheimer’s
disease. Studies have also shown that the neuropathology of postmortem Alzheimer’s
brains involves a significant decrease in nAChRs compared to that of normal ageing
(Court et al., 2001). Because nicotine administration results in an upregulation of
nAChRs, this effect could help delay some of the more severe cognitive deficits of the
disease by keeping the nAChR level in the brain stable and increasing neurotransmission.
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Studies of nicotine’s effects in humans are generally carried out using injections,
nasal sprays, or transdermal nicotine patches. These methods of nicotine administration
cause nicotine to reach the brain much more slowly and are less likely to lead to a
nicotine addiction than smoking, in which nicotine reaches the brain extremely rapidly
(Samaha et al., 2005). The first study investigating the effects of intravenous nicotine
administration on Alzheimer’s patients used extremely small doses of nicotine, and found
that even when the dose was as small as 0.25 μg/kg/min, AD patients showed decreased
errors on a test of cognitive function (Newhouse et al., 1988). In studies using acute
nicotine doses of 0.4 to 0.8 mg, significant cognitive enhancement was demonstrated in
normal controls as well as Alzheimer’s patients on various tests of attention and cognitive
function (Jones, Sahakian, Levy, Warburton, & Gray, 1992; Sahakian, Jones, Levy, Gray,
& Warburton, 1989). More recently, however, the transdermal nicotine patch has been
used in order to provide a larger dose and to avoid the necessity of injections. In a pilot
study demonstrating the effects of the nicotine patch in AD patients, Wilson and
colleagues (1995) demonstrated that the nicotine group (still receiving a moderate dose—
0.9 mg/hr) showed improved learning. This was a result that had not been previously
reported (early studies only showed improved attention), and it paved the way for further
research in this area (Wilson et al., 1995).
In 1999, White and Levin investigated the effect of a 5 mg transdermal nicotine
patch when worn by patients with mild to moderate Alzheimer’s disease, and found that
the nicotine significantly improved patients’ performance on a task of attention, but there
were no significant differences relating to motor or memory function (White & Levin,
1999). Later, White and Levin (2004) performed a similar study using 5 mg transdermal
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nicotine patches on patients with age-associated memory impairment (AAMI), which has
milder cognitive deficits than AD. Using the same scale as in the previous study (the
Conners’ Continuous Performance Test), they were able to demonstrate the same increase
in attention as a result of the nicotine administration in AAMI patients (White & Levin,
2004). Though in White and Levin’s studies no significant effects were seen in memory,
studies using nicotinic receptor agonists that report an improvement in declarative
memory, as well as the Wilson et al. (1995) study that showed improved learning,
provide evidence that nicotine can help alleviate the memory deficits found in AD and
other diseases affecting cognition (Potter et al., 1999).
Parkinson’s Disease
In addition to nicotine’s positive effect on patients suffering from diseases that
primarily affect cognition, nicotine has also been shown to be therapeutic in Parkinson’s
disease (PD), a neurodegenerative disease characterized by impairments in motor
coordination and function (Quik, 2004). The neuropathology of PD involves damage to
dopaminergic nigrostriatal neurons. This leads to the motor deficits of the disease, which
include tremor, rigidity, akinesia, bradykinesia, and gait disturbances (Mazziotta, Toga,
& Frackowiak, 2000; Quik, 2004). Though not as prevalent as the motor symptoms,
patients with Parkinson’s disease can also suffer from dementia, which is one of the
reasons nicotine has been investigated as a potential therapeutic agent (Quik, 2004). This
branch of research was first investigated after a series of studies emerged suggesting that
Parkinson’s disease is less prevalent in cigarette smokers, and that smoking can
potentially delay the onset of the disease (Fujita et al., 2006; Quik, 2004). It was thought
that the nicotine in cigarettes played a key role in this delay due to its stimulation of
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dopaminergic nigrostriatal neurons, and its neuroprotective effects (Quik, 2004). In
addition to this, a neuroimaging study comparing nAChR expression in normal controls
vs. Parkinson’s patients concluded that patients with PD display a significant decrease in
nAChRs, and that nicotine could be beneficial to these patients as well as patients with
other neurodegenerative disease because it stimulates these receptors (Fujita et al., 2006).
A longitudinal study investigating the effects of high-dose nicotine administered
via transdermal patches on Parkinson’s patients confirmed the hypothesis that nicotine
can be beneficial to such patients (Villafane et al., 2007). Patients were given increasing
daily doses of nicotine (5-105 mg/day) for 14 weeks, keeping the highest tolerated dose
constant for at least 4 weeks before gradually decreasing the dose until the conclusion of
the experiment at week 29. Though most patients experienced symptoms of nausea and
insomnia, all patients demonstrated improved motor ability and required less of their
usually prescribed dopaminergic drugs by the end of the study (Villafane et al., 2007).
The ideal daily dose was determined to be between 45 and 90 mg/day, and because this
study was done over such a long duration, it provides convincing findings regarding
nicotine’s potential as a therapeutic agent for the motor symptoms of Parkinson’s disease
(Villafane et al., 2007).
Schizophrenia
Schizophrenia, a type of recurring psychosis that can have detrimental effects on
cognition, emotion, perceptions, and even motor function, is another illness that has long
been known to have a therapeutic tie to nicotine (Kraly, 2006; Postma et al., 2006).
Schizophrenics often show much higher rates of cigarette smoking when compared to the
general population, so studies involving nicotine and schizophrenia can be very useful in
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order to better understand the disease (Postma et al., 2006; Smith, Singh, Infante,
Khandat, & Kloos, 2002). Schizophrenics have difficulty ignoring irrelevant sensory
input, and often show impairment in acoustic prepulse inhibition (PPI). PPI is
characterized by a decrease in the magnitude of response to a startling stimulus when the
stimulus is preceded by a lower intensity, non-startling stimulus (Postma et al., 2006). In
schizophrenic patients, the reaction to the startling stimulus is not lessened by the
prepulse, thus causing an overload of information that would not occur in normal patients
(Kumari, Soni, Mathew, & Sharma, 2000).
Nicotine has been shown to enhance PPI in both normal controls and
schizophrenic patients, and a functional magnetic resonance imaging (fMRI) study
showed that the increase in PPI as a result of the nicotine appeared largely in the
hippocampus (Postma et al., 2006). In addition to improved PPI, nicotine administered
via nasal spray has been demonstrated to improve cognition (through verbal memory
tasks and spatial organization tasks) in schizophrenics and has also led to improved
performance on oculomotor and attention tasks (Depatie et al., 2002; Smith et al., 2002).
These results suggest that the increase in smoking in schizophrenic patients is possibly a
form of self-medication, and provides evidence for a schizophrenia treatment involving
another method of nicotine administration that does not include the added risks associated
with cigarette smoking.
Attention Deficit/Hyperactivity Disorder
Because of the clear evidence that nicotine has a positive effect on attention,
studies have also been carried out to demonstrate nicotine’s effect on adults with
Attention Deficit/Hyperactivity Disorder (ADHD). ADHD is characterized by symptoms
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of inattention and hyperactivity that are severe enough to interfere with daily life
(Sharkey & Fitzgerald, 2007). As would be expected, administration of nicotine to
ADHD patients leads to improved performance on tasks of attention, such as the
Conners’ Continuous Performance Test (CPT), and has also been reported to decrease
reports of depressed mood (Levin et al., 1996; Rezvani & Levin, 2001). Nicotine patches
administering 7 mg of nicotine to non-smoking ADHD patients showed an overall
nicotine-induced improvement on a modified version of the Clinical Global Impressions
(CGI) scale, as well as improving scores on the CPT (Levin et al., 1996).
From the numerous studies investigating the administration of nicotine to people
with diseases affecting different aspects of cognition, it can be inferred that nicotine can
be extremely beneficial to people suffering from a variety of illnesses. In illnesses like
Parkinson’s disease, schizophrenia and ADHD, adult patients have been shown to self
medicate with cigarettes, and evidence points to this being due to the nicotine they
receive (Levin, McClernon et al., 2006). Smoking, however, adds numerous risks due to
the toxins found in the smoke that cause lung damage and cancer, as well as the addictive
properties of nicotine when delivered in such high doses (Winger et al., 2004). Thus, if
nicotine can be administered in a more controlled and safe manner as a therapeutic agent,
patients would not have to be subjected to the risks associated with cigarette smoking.
Animal Models and Working Memory
Due to experimental limitations in human nicotine studies, much of the
preliminary and ongoing research regarding nicotine’s effects on cognition has come
from studies of non-human animals. Nicotine has been shown to have a significant effect
on cognition in non-human animals in various behavioral tasks that demonstrate working
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memory. Working memory is an updated term for short-term memory, and it involves
the storage of information that is currently in use, or that is likely to be needed in a short
amount of time (Hegarty & Waller, 2005; Schumann et al., 2004). Working memory can
include verbal (in humans), object, and spatial tasks, and it is relatively easy to test this
type of memory function in lab animals using object recognition tasks, the Morris Water
Maze, or the Radial Arm Maze (Hegarty & Waller, 2005; Schumann et al., 2004). An
example of nicotine’s effect on working memory can be demonstrated by the
performance of rats in an object recognition task: Rats that were given an acute dose of
nicotine demonstrated improved working memory compared to normal controls due to a
clear increase in the recognition of an old object vs. a new object (Puma, Deschaux,
Molimard, & Bizot, 1999). In addition to this, zebrafish that were exposed to an acute
dose of nicotine for 3 minutes showed increased performance in a spatial position
discrimination task (Levin, Limpuangthip et al., 2006).
One way to demonstrate working memory is to expose rats to the Radial Arm
Maze (RAM), which consists of a maze with arms extending out from a center (the
number of arms varies based on the study), and a reward at the end of each arm (usually a
food treat). Rats should only venture down each arm once until all rewards are received,
and any time a rat re-enters an arm, it is marked as an error. In this way, working
memory can be assessed by the extent to which the rat remembers what arms it has
already been down. In a study assessing the effects of acute and chronic nicotine on
young and aged rats in the RAM, Levin and Torry (1996) found that the young rats
treated with chronic nicotine showed an increase in working memory, but the aged rats
did not show the same increase. There was no significant improvement in working
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memory after acute doses of nicotine in the young rats, but there was a pronounced effect
of the acute administration of nicotine in the aged group (Levin & Torry, 1996). These
findings suggest that a chronic dose of nicotine may be more effective in cognitive
enhancement in young rats, while aged rats may benefit more from acute doses
administered immediately prior to a task (Levin & Torry, 1996). These findings contrast
slightly with the findings of French and colleagues (2006), who tested aged rats with a
chronic nicotine dose of 0.3 mg/kg in the RAM. They found nicotine significantly
increased working memory in these rats, and suggested that the lower dose in aged rats
helped improve performance due to their decreased metabolism of the nicotine (French,
Granholm, Moore, Nelson, & Bimonte-Nelson, 2006). In the Levin and Torry (1996)
study, the dose given to both groups was 0.5 mg/kg. It is possible that this dose was
effective for the young rats, but too much for the old rats when administered chronically.
Another commonly used method to demonstrate increased cognition in rats
exposed to nicotine is to test them in the Morris water maze (MWM) to determine their
cognitive spatial abilities. The MWM is a large circular maze filled with opaque water,
and rats (or mice) must locate a hidden platform using spatial cues surrounding the maze
(Morris, 1984). At the start, rats are placed on the platform so they can become
acclimated to the maze and exposed to the spatial cues that surround it. Then they must
learn that there is no escape from the maze via the outside walls, and they must utilize the
spatial cues around the maze to locate the platform. Full acquisition of the task occurs
when the swim times decrease and level off, and remain low when the rats are placed at
varying start locations around the maze (Morris, 1984). Studies have demonstrated that
rats differ in performance in the Morris water maze based on age, gender, and sometimes
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strain (Hansalik, Skalicky, & Viidik, 2006; Topic et al., 2005). Age differences are
apparent in that aged rats tend to have more difficulty in the acquisition of the water maze
task compared to young rats, however according to a study by Topic and colleagues
(2005), there is considerable variability due to individual differences. Thus, while most
aged rats were slower than the young rats, there were some aged rats who had swim times
that were on par with those of the youngest and fastest rats (Topic et al., 2005). Early
training, however, can decrease response times of aged rats compared to aged rats with
no previous training, suggesting that the MWM is also a tool for assessing long-term
memory retention (Hansalik et al., 2006).
In nicotine studies examining spatial learning, the dose administered and length of
administration prior to training are extremely important. A study using mice
demonstrated that a nicotine dose of 0.7 mg/kg/day produced significant impairment in a
water maze task, but 0.35 mg/kg/day administered intraperitoneally 5 days prior to
training and throughout training itself produced significantly lower trial latencies (Bernal,
Vicens, Carrasco, & Redolat, 1999). Thus, it is important not only to administer a low
dose of nicotine, but also to administer it a few days prior to the task to allow the drug to
take its full effect (Bernal et al., 1999). The extra time needed is most likely due to the
fact that receptor upregulation, which can enhance the effect the nicotine has on the brain,
takes some time to occur. Nicotine doses as low as 0.2 mg/kg have been shown to have
an effect on both young and older rats, and these studies have also utilized the technique
of waiting a few days prior to the first acquisition trials in order for the drug to take effect
(Socci, Sanberg, & Arendash, 1995). Using a dose of 0.2 mg/kg not only results in
enhanced water maze acquisition in aged rats, but it also has been shown to improve
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memory retention in young rats (Socci et al., 1995).
It has also been reported that high doses of nicotine do not demonstrate nicotine’s
positive effects due to ACh receptor desensitization. Receptor desensitization occurs
when a neurotransmitter binds to a receptor but the ion channel, through which positively
charged ions would normally travel to lead to an EPSP, remains closed (Benwell et al.,
1995). Thus, though the neurotransmitter is bound to the receptor, an action potential
does not occur and the neuron does not fire. Because of this desensitization (which
occurs when rats are administered high levels of nicotine that are on par with the amount
a regular smoker may receive, 1.0 and 4.0 mg/kg/day for this particular study), the effect
of the nicotine on memory and learning is actually inhibitory (Benwell et al., 1995).
Lower doses of nicotine, for example, 0.25 mg/kg/day, did not show this desensitization,
and thus still shows cognitive enhancement in spatial learning studies (Benwell et al.,
1995).
Long-Term Potentiation
Studies involving nicotine treatment in working memory tasks are also beneficial
in that they can provide evidence for nicotine’s inducement of Long Term Potentiation
(LTP). As was mentioned earlier, LTP occurs in the hippocampus and results in an
increase in synaptic firing and effectiveness (Schumann et al., 2004). LTP is an
important part of memory formation, and it has been shown to occur throughout the
neuronal information pathways in the brain (Schumann et al., 2004). This process also
involves the upregulation of glutamate NMDA receptors, which have been shown to be
modulated by nicotine in some studies of working memory in rats (Levin, Bettegowda,
Weaver, & Christopher, 1998).
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One study looked at nicotine’s effect on LTP in the rat hippocampus by assessing
its therapeutic effects in rats suffering from working memory impairments. The working
memory impairments were induced by stress, and the subcutaneous administration of 1
mg/kg of nicotine prevented the memory impairments associated with the stressor
(Aleisa, Alzoubi, Gerges, & Alkadhi, 2006). The nicotine served to normalize the LTP
that had been reduced in the stressed rats treated with saline. This suggests that nicotine
does have neuroprotective effects regarding memory and learning, so much so that it can
counteract the impact of a stressor in rats (Aleisa et al., 2006). The control rats in the
study that were not exposed to the stressor but received nicotine treatment did not show
any learning or memory improvement, however this could be due to the extremely high
dose (1 mg/kg) of nicotine that was administered. It has already been demonstrated that
high doses can show water maze impairment, so it is possible that such a high dose is
only necessary to reverse the effects of cognitive impairment, not to enhance the
performance of otherwise normal rats (Bernal et al., 1999).
It has also been demonstrated that nicotine can attenuate working memory
impairments caused by dizocilpine, an NMDA glutamate receptor antagonist, providing
more evidence for nicotine’s neuroprotective effects (Levin, Bettegowda et al., 1998).
NMDA glutamate receptors are known to be upregulated as a result of LTP, so the
attenuation of these impairments could be due to an increase of LTP as induced by the
nicotine. Because the nicotine stimulated the release of glutamate, it was able to
counteract the drug and reverse the working memory impairments, though it did not
increase performance in the radial arm maze. When the dose of nicotine (0.4 mg/kg) was
given without the dizocilpine, an increase in maze performance was also not detected—it

Effects of Nicotine 22
is possible that this dose was too high to produce positive effects, as it has been
demonstrated that a dose of 0.7 mg/kg in mice actually causes impairments in spatial
learning tasks (Bernal et al., 1999; Levin, Bettegowda et al., 1998). In a later study
involving dizocilpine and nicotine, the nicotine dose of 0.4 mg/kg led to inconclusive
results regarding its neuroprotective effects. This suggests that 0.4 mg/kg may be at
some kind of dose threshold where the effects of the nicotine switch from positive to
negative (Levin et al., 2003).
Neurogenesis
In past studies demonstrating nicotine’s attenuation of working memory
impairments, a case has been made that nicotine can be neuroprotective, meaning it
minimizes the damage done by certain drugs or events by stimulating the release of
neurotransmitters such as glutamate or dopamine (Levin, Bettegowda et al., 1998).
Despite this, a study has indicated that nicotine actually decreases neurogenesis in the
brain when self-administered by rats (Abrous et al., 2002). However, in this study, the
self-administration aspect led rats to have plasma nicotine levels that were extremely high
and equivalent to those of smokers—the rats in cognitive enhancement studies as well as
humans in controlled nicotine patch studies do not receive such high levels of nicotine
(Abrous et al., 2002). It has already been reported that such high nicotine levels
desensitize important receptors involved with the release of both glutamate and
dopamine, neurotransmitters essential to memory and learning (Benwell et al., 1995).
For this reason, it makes sense that large amounts of nicotine may actually decrease
neurogenesis in the brain.
Studies employing the use of bromodeoxyuridine (BrdU) are essential in
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demonstrating the effects of spatial learning tasks on neurogenesis, and can indicate
whether nicotine has any effect on the cell proliferation. When injected intraperitoneally,
BrdU incorporates into the DNA of all cells undergoing synthesis at the time of learning.
The BrdU stays in these cells and can be detected post-mortem through
immunohistochemical procedures (Cooper-Kuhn & Kuhn, 2002). It has been
demonstrated that an increase in newly-generated cells in the hippocampus occurs due to
the process of learning itself—not just training (Dalla, Bangasser, Edgecomb, & Shors,
2007). Even when the task was not hippocampus dependent, rats that “learned well,” that
is, that demonstrated a high acquisition of the task after its completion, showed increased
cell proliferation compared to rats that did not learn well, thus emphasizing the
importance of learning rather than training (Dalla et al., 2007). BrdU studies have also
clearly shown that neurogenesis decreases significantly from adolescence to adulthood,
though neurogenesis in the hippocampus is still apparent in adults as a result of certain
tasks involving learning (He & Crews, 2007). Though the cell growth seen as a result of
the Morris water maze task is generally attributed to the learning that occurs during the
late phase of this task, there is also evidence that exercise can increase cell proliferation
as well (van Praag, Kempermann, & Gage, 1999). This suggests that tasks involving
exercise, such as the Morris water maze, could be even more indicative of cell
proliferation in the hippocampus.
Morris water maze studies involving BrdU injections can provide useful results
regarding neurogenesis in the hippocampus as a result of the learning that occurs during
the task. In one Morris water maze BrdU study, the early phase of learning, in which
there is a rapid improvement in performance, did not produce significant cell
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proliferation, while the late phase of learning, during which the highest point of
performance is reached, demonstrated a significant increase in the number of newly
generated cells (Dobrossy et al., 2003). This was thought to potentially be due to the
stress of the early phase of learning, in which rats were becoming acclimated to the
task—for this reason, perhaps, neurogenesis was dampened at that time (Dobrossy et al.,
2003). Neurogenesis in the late phase, it was hypothesized, could indicate that the
dentate gyrus of the hippocampus was available for the integration of new information
and the storage of new memories at that phase of learning (Dobrossy et al., 2003).
Studies using lower doses of nicotine in tasks that are known to produce
neurogenesis in the brain, particularly in the hippocampus, have shown that low doses of
nicotine do not have a detrimental effect on neurogenesis (Scerri, Stewart, Breen, &
Balfour, 2006). In accordance with the findings of previous studies, Scerri and
colleagues (2006) concluded that a nicotine dose of 0.4 mg/kg per day had an adverse
effect on neurogenesis (as demonstrated by a BrdU investigation), but rats receiving 0.25
mg/kg per day showed an increase in cell proliferation in response to the Morris water
maze task. This study provides further evidence that learning associated with the Morris
water maze task can be demonstrated clearly in the dentate gyrus of the hippocampus,
and that nicotine may have a positive impact on the cell proliferation that occurs there
(Scerri et al., 2006).
c-Fos Expression
In addition to increased cell proliferation, it has been widely reported that nicotine
produces an increase in c-Fos expression in various areas of the brain (Guan, Kramer,
Bellinger, Wellman, & Kramer, 2004; McCormick & Ibrahim, 2007; Panagis, Nisell,

Effects of Nicotine 25
Nomikos, Chergui, & Svensson, 1996; Salminen, Lahtinen, & Ahtee, 1996). c-Fos is a
protein that indicates neuronal activation, and it has often been studied in relation to
stress (Kovacs, 1998; McCormick & Ibrahim, 2007). In a study combining stressors with
nicotine treatment in adolescent male and female rats, it was found that males showed an
increase in c-Fos in the hypothalamus while females did not, and chronic nicotine groups
showed more c-Fos expression than did acute nicotine groups (McCormick & Ibrahim,
2007). From these results, it can be hypothesized that nicotine must be chronically
present in the system in order to have an effect on c-Fos expression in the brain. It has
also been found that nicotine significantly increases c-Fos expression in brain areas
specifically related to stress, such as the paraventricular hypothalamic nucleus and the
supraoptic nucleus (Salminen et al., 1996).
The rate of nicotine delivery can also have an effect on c-Fos expression (Samaha
et al., 2005). In one study, rats were infused with either 25 or 50 µg/kg nicotine in a time
span of 5, 25, or 100 seconds. The results showed that c-Fos expression and receptor
sensitization were highest when the infusion rates were fastest. High administration rates
are thought to be central to the addictive properties of nicotine, and perhaps the increase
in c-Fos expression is a result of the rapidly increasing occupancy of nicotinic receptors
that occurs when nicotine is delivered at a fast rate (Samaha et al., 2005).
Nicotine can also cause Fos increases in areas of the brain specifically related to
dopamine transmission, such as the nucleus accumbens and the caudate-putamen. In a
study looking at both c-Fos and ∆FosB (another member of the Fos family that stays in
the brain longer and has been linked to drug addiction), nicotine was shown to increase
both Fos types in these dopaminergic brain areas, providing further support for nicotine’s
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role in increasing dopamine transmission (Marttila, Raattamaa, & Ahtee, 2006). The
increase that nicotine causes in locomotor activity, also known as behavioral
sensitization, has also been related to an increase in Fos in the nucleus accumbens, the
striatum, and the ventral tegmental area, again providing support for nicotine’s role in the
dopamine release process, and providing further evidence for its rewarding properties
(Shim et al., 2001).
Increased c-Fos expression in nicotine studies is also dependent on the nicotine
dose used. One study found that a nicotine dose of 2 mg/kg showed the most dramatic
expression of c-Fos in the brain, while the lower doses of 0.5 mg/kg and 1mg/kg showed
minimal increase in c-Fos (though these doses did still produce an increase when
compared to normal controls) (Ren & Sagar, 1992). Other studies have shown an
increase in c-Fos expression in their brain areas of interest (for example, the
hypothalamus, the visual pathways, the striatum) using doses of 0.4 mg/kg, (Shim et al.,
2001), 0.5 mg/kg (McCormick & Ibrahim, 2007), and 1mg/kg (Salminen et al., 1996).
Though these doses are slightly higher than those used in spatial learning studies, the fact
that they produce c-Fos expression suggests that lower doses may still lead to an increase
in expression when compared to normal controls.
The fact that chronic nicotine shows an increase in c-Fos in certain brain areas
provides support for the idea that neurons may undergo changes in gene expression due
to nicotine exposure (Ren & Sagar, 1992). This alteration of neuronal gene expression,
which could potentially be long-term, would be beneficial to people suffering from
diseases that affect cognition because it could mean an increase in nAChrs, which would
increase their cognition and potentially delay the onset of cognitive decline (Ren &
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Sagar, 1992).
The purpose of the current study was to assess the effects of a chronic dose of
nicotine on the ability of rats to acquire the Morris water maze task in adolescence and
adulthood. Previous studies of chronic nicotine administration have indicated that doses
around 0.2 mg/kg serve to increase cognitive functioning, and that higher doses run the
risk of adversely affecting maze performance (Bernal et al., 1999; French et al., 2006;
Socci et al., 1995). For this reason, we used 0.2 mg/kg as our dose for rats of all age
groups.
Because most of the previous studies involve specifically young or aged rats, this
study was unique in that it examined the effects of nicotine on the same rats in
adolescence (Phase 1) and adulthood (Phase 2). The schedule of nicotine was also varied
based on the groups. There were four main groups: rats that received nicotine in Phase 1
during adolescence and nicotine again in Phase 2 when they reached adulthood (N/N),
rats that received nicotine in Phase 1 and saline in Phase 2 (N/S), rats that received saline
in Phase 1 and nicotine in Phase 2 (S/N), and rats that received saline in Phases 1 and 2
(S/S). In Phase 1, rats were trained in the Morris water maze while receiving either 0.2
mg/kg of nicotine or saline for 2 weeks, and then nicotine or saline administration was
ceased until four months later. At this time, drug treatment was resumed based on the
group, and Morris water maze testing was repeated in the same fashion. Additionally,
Bromodeoxyuridine (BrdU) injections were introduced into the study during the last two
days of Phase 2 acquisition in order to view possible neurogenesis as a result of the
nicotine exposure and water maze training (Scerri et al., 2006).
Though this study involved nicotine cessation after a 2-week period of chronic
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nicotine administration, the rats were not expected to experience serious withdrawal
symptoms. A study investigating withdrawal from chronic nicotine showed that even
after an extremely high dose (22.2 mg), withdrawal symptoms in adolescent rats were
minimal, even after the immediate introduction of a nicotinic agonist (Wilmouth & Spear,
2006). Adult rats showed minor withdrawal symptoms that abated shortly after nicotine
cessation (Wilmouth & Spear, 2006). This finding, coupled with the fact that the dose
was significantly higher in these studies, suggests that the rats in the present study were
not in danger of severe withdrawal symptoms in the interim between phases.
The purpose of the varying nicotine schedules was to determine whether learning
was state dependent (for the N/N group), whether early experience had a greater effect on
task acquisition (for the N/S group), or whether the effect of nicotine was more
pronounced in older rats (for the S/N group). The rats that received saline in both phases
served as a control for this experiment. It was expected that, in both phases, nicotine rats
would perform better than saline rats in the Morris water maze. Due to the previous
training that the rats received in Phase 1, it was expected that reaction times would be
faster overall in Phase 2 during the re-acquisition of the task, however it was
hypothesized that rats receiving nicotine in Phase 2 would re-acquire the task faster than
rats not receiving nicotine, and that rats receiving nicotine in both phases would be better
at the task overall (Hansalik et al., 2006).
It was also expected that rats in all groups would show an increase in cell
proliferation in the hippocampus due to the water maze task, and that the Phase 2 nicotine
rats would have more BrdU expression than the saline rats due to previous studies
suggesting nicotine is neuroprotective and involves nAChR upregulation (Dobrossy et
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al., 2003; Wang et al., 2008). We also tested for c-Fos in the hippocampus following the
last day of training in the second phase of testing for all rats. Based on previous studies
indicating that chronic nicotine at doses of 0.5 mg/kg to 2 mg/kg increase c-Fos
expression in certain brain areas, we expected c-Fos levels to be elevated in rats receiving
nicotine in Phase 2 (McCormick & Ibrahim, 2007).
We specifically looked at c-Fos expression in the dentate gyrus of the
hippocampus. A previous study examining nicotine’s effect on c-Fos in the pigeon brain
reported the hippocampus to be one of the greatest sites of c-Fos expression, however to
our knowledge a study investigating c-Fos expression in the rat hippocampus following
nicotine exposure and a spatial learning task has not previously been attempted
(Chadman, Woods, & Stitzel, 2007). For this reason, the present research provides
important results regarding the effect of nicotine on c-Fos in the hippocampus and the
implications this has regarding spatial learning. A significant c-Fos increase in the
hippocampus may provide even further evidence that nicotine has a significant effect on
cell growth and receptor upregulation in this brain area, as c-Fos is generally an indicator
of the beginnings of neuronal change and activity (McCormick & Ibrahim, 2007; Ren &
Sagar, 1992).
Method
Subjects
Subjects included 50 male Fisher-344 rats born at the Charles River Laboratories
in Stoneridge, NY, USA. Rats from all cohorts were 6 weeks old on arrival. The study
began 2 weeks later, at which time rats in Cohort 1 (numbers 1-16) weighed between 160
g and 185 g, rats in Cohort 2 (numbers 17-35) weighed between 155 g and 180 g, and rats
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in Cohort 3 (numbers 36-50) weighed between 150 g and 180 g. Five months later
during Phase 2 of the experiment, Cohort 1 weighed between 305 g and 340 g, and
Cohort 2 weighed between 300 g and 345 g, with one rat weighing 276 g.
Rats were housed 3 or 4 to a clear plastic cage measuring 19 x 9 x 9 in. They
were given regular shavings, water, and rat chow. Some of the rats from Cohorts 1 and 2
were given wet food along with the dry food a few months into the study due to slightly
decreased weight that may have been the result of a mouth infection. Rats were also
given a square red Plexiglas tube to use as a shelter.
Procedures were approved by the Connecticut College Animal Care and Use
Committee in accordance with the guidelines of the USDA and the Office of Laboratory
Animal Welfare.
Apparatus
Alzet osmotic mini-pumps (model 2004, Braintree Scientific, Braintree, MA)
were used to administer a chronic dose of 0.2 mg/kg of nicotine or saline per day for a 2week period.
Activity levels were recorded in an activity box measuring 42 x 45 cm on the
inside and 11 cm high, with a normal rat cage, measuring 42 x 22 cm and 21 cm high,
inside of it. The normal cage was made of transparent plastic and had a metal lid and
wood shavings for bedding. The activity box surrounding the cage was made of metal
and measured the activity of the rat. There was a light beam on one side of the cage
projecting to the other side, which measured beam crossings (the amount of times the rat
interrupted the light). This provided a quantitative measurement of the rat’s movements.
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Spatial learning was tested using a Morris water maze. The maze was a large
white plastic tub that was 4 ft in diameter. The water level was kept at 13 in, with the
platform approximately 0.5 in below the water level. The platform was a tall Plexiglas
tube with a petri dish fitted to the top. A white washcloth was attached to the top of the
platform with a rubber band. The platform was kept stationary, 11 in from the right side
of the maze, using a weight at the base. The water was made opaque with white tempera
paint, which was mixed thoroughly in the water prior to each acquisition and test day.
The water was kept at 20 °C during all experimental trials.
The maze was in a rectangular shaped room with white walls and various
stationary visual cues surrounding it. The visual cues included rectangular pieces of
construction paper with different shapes (circles, a star, stripes) of contrasting color on
top of them. The metal temperature gauge and hose, as well as the open door and the
experimenter’s position also acted as visual cues, and remained constant during the
experiment. The maze was 10.5 in away from the two longer walls, and 17 in away from
the shorter wall farthest from the door to the room.
Procedure
Rats were allowed to acclimate to their new surroundings for one week prior to
being handled and weighed for the first time. The rats were handled for approximately 3
minutes each on at least two separate occasions prior to their first day of surgery. Weight
measurements (in grams) were taken two days prior to surgery, as well as the day of
surgery in all cases, in order to ensure the rats were gaining weight at a normal pace and
to make the measurement of the necessary anesthetic as accurate as possible. Activity
levels were taken on the day of the last surgery for all groups in order to determine
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possible changes in locomotion in the nicotine rats. The early phase of acquisition trials
in which Cohorts 1 and 2 (these two cohorts make up what is later referred to as the dualphase cohort) were first exposed to the experimental procedure was considered Phase 1.
Cohort 1 initially contained 16 rats, however due to some complications with the pumps
the data from 2 of the rats was not used. Cohort 2, containing rats that arrived one week
after Cohort 1 with all of the same specifications, included 18 rats. One rat died during
the surgical procedure, so its data was not used in the experiment. At this time, rats were
given either nicotine or saline for the experimental procedure. See Table 1 for a
description of the drug treatments and number of subjects in each group.
During Phase 2 of testing, rats in the dual-phase cohort were broken up into four
groups, N/N, N/S, S/N, and S/S, depending on what drug treatment they received in
Phases 1 and 2 (see Table 1). The purpose of the N/N rats was to indicate whether
acquisition of the procedure was state-dependent. The N/S rats were to demonstrate
whether early experience had a greater effect on task acquisition than the nicotine itself.
The S/N rats were to demonstrate whether the effect of the nicotine would be more
pronounced in older rats, and the S/S group acted as a control for the three other groups.
The 16 rats in Cohort 3 (the single-phase cohort) contained the same
specifications as all previous rats, and underwent the same procedure, with 8 receiving
nicotine pumps and 8 receiving saline pumps. One rat died during the procedure, leaving
7 nicotine rats and 8 saline rats. After one phase of acquisition and test trials, these
animals were sacrificed and their brains were examined for neurogenesis (as evidenced
by BrdU) and c-Fos in the hippocampus. In this way they acted as a control for age, as
their results were expected to provide insight into the c-Fos and BrdU expression that
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might occur in adolescent rats as a result of nicotine exposure. They did not undergo a
second testing phase.
Approximately 24 hours prior to the surgery the pumps were set up following the
procedure as outlined by the Alzet company. The nicotine was mixed using 0.2859
grams of nicotine per 3 ml of saline. This concentration allowed the animals to receive
0.2 mg/kg per .29 µl nicotine base per day, while the control animals would receive an
equal volume of vehicle (saline) per day. In order to fill the pumps, the empty pump was
first weighed along with the flow moderator. Solution was drawn into a 1 ml syringe and
a 27 gauge filling tube (provided by the Alzet company) was fit to the end of it. The
empty pump was held upright and filled slowly, ensuring there were no air bubbles in the
pump. When the solution appeared at the outlet of the pump, the filling tube was
removed and excess solution was wiped off. The flow moderator was then inserted until
it was flush with the pump, and the displaced solution was wiped off. The pump was
then weighed again, ensuring that the difference in the weight from the empty pump gave
the proper net solution of the pump, 30 μl. Pumps were then incubated in sterile saline
and allowed to equilibrate at 37 °C overnight.
On the day of surgery, all animals were weighed in order to ensure an accurate
dosage of anesthetic. The anesthetic was prepared by mixing 1.95 ml of xylazine and 1.8
ml of ketamine. In order to determine the specific amount of anesthetic necessary for
each rat, 1.25 ml was multiplied by the most recent weight measurement in kilograms.
The result, usually hovering around 0.2 ml, was administered intraperitoneally and the
rats were put in a covered cage as the drug took effect. Once the rat was asleep, a small
area between the shoulder blades was shaved, and a vertical incision was made in the

Effects of Nicotine 34
skin. The pump was then inserted subcutaneously. The wound was then closed with two
metal clips, and the rat was placed in another covered cage until the anesthetic wore off.
This procedure was repeated for each rat.
During the first surgeries for Cohort 1, the pumps were inserted with the top of
the pump facing the wound. Due to the complications of a few of the pumps coming out
because of excessive scratching, it was determined that the release of nicotine may have
been irritating the wound. Thus, all other surgeries were conducted by inserting the top
of the pump first.
Two days after the surgery all rats were weighed to ensure they did not lose a
significant amount of weight as a result of the drug. The rats were given 7 days prior to
the acquisition trials for the drug to begin to take effect. After this time had elapsed, all
rats were tested in the Morris water maze.
Testing began daily at 4:00 pm, and usually lasted between 1.25 and 2 hours.
Prior to the first trial on Day 1 of acquisition, all rats were placed on the platform for 60
seconds so they could become acclimated to their surroundings. During the acquisition
trials, rats were positioned at start location 1 (see Figure 1) and a time measurement was
taken with a stopwatch to measure how long it took them to reach the platform. If any rat
failed to reach the platform after 60 seconds of swimming during any given trial, the rat
was removed from the maze and placed on the platform for another 60 seconds.
Acquisition involved five trials from start location 1 per day for five consecutive
days. Rats were tested by cage, so trials were alternated between 4 rats at a time in order
to avoid fatigue from completing multiple trials per rat in succession. After the fifth day
of acquisition trials there were two days without any trials, followed by one day of test
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trials (see Table 2). During the testing day, the first trial was at the familiar start location
(start location 1), and the remaining 4 trials began at varying start locations around the
maze (see Figure 1 for a diagram of the maze and start locations). These start locations
remained constant throughout the study.
It should be noted that during the first day of acquisition trials for Cohort 1 in
Phase 1 of testing, 10 acquisition trials were taken per rat (as opposed to 5). It was
determined that this number was too high, as latencies began to increase toward the end
of the acquisition period. The increase was most likely due to fatigue, and thus all
acquisition days following that first day involved only five trials, and only the first five
trials from acquisition day 1 for Cohort 1 were used in the data analysis.
After the week of testing was over, rats were weighed, activity levels were
recorded in an activity box for five minutes, and then they were anesthetized using the
same procedure as outlined previously. The pumps were removed and the rats from the
dual-phase cohort were kept until Phase 2 of testing, which occurred four months later.
These rats were weighed once a week in between testing phases.
Acquisition and testing for the single-phase cohort and Phase 2 of the dual-phase
cohort were subject to a slightly different procedure. Surgery was performed on these
rats as per usual, and acquisition trials began one week following the procedure. The
procedure for acquisition trial days 1-4 were identical to those of Phase 1 of the dualphase cohort, however after the fourth day one day was skipped, and the last day of
acquisition was on the sixth day of the experiment. The test trials were on the day
immediately following the last day of acquisition (day 7), in order to allow for perfusion
of rats that coincided with the test trials and the injection of BrdU (see Table 2 for the full
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experimental schedule). This change in procedure was due to complications with the
BrdU, however it was not expected that any significant difference would arise due to this
change. The order in which the trials occurred and the small timing changes of the
testing trials were not expected to have any effect on the ability of the rats to perform the
task and to recall it during testing.
BrdU was introduced during Phase 2 acquisition trials for the dual-phase cohort,
and during the acquisition trials of the single-phase cohort. BrdU was mixed in a
concentration of 25 mg/ml in physiological saline. It was necessary to warm the solution
in order for the BrdU to dissolve. Once the BrdU was in solution, rats were weighed, the
proper amount for injection (2 ml/kg) was calculated, and rats were injected at roughly
4:30 pm during the free day between acquisition days 4 and 5. The second BrdU
injection occurred 30 minutes prior to acquisition trials on acquisition day 5, which was
one day prior to test trials. Two rats from the dual-phase cohort did not receive the BrdU
injection, as they were aggressive and difficult to inject.
Rats were perfused 90 minutes after their last test trial in order to preserve the
brains to look at c-Fos and incorporation of BrdU in the hippocampus. This process
involved euthanizing the rat and perfusing the body with the fixative 4% PFA, then
removing the brain and soaking it in the fixative overnight. The following day, the brain
tissue was transferred to a 30% sucrose mixture. Using a cryostat, the brain tissue for
each rat was then frozen and sliced at 25μm through the dentate gyrus of the
hippocampus. The sections of brain tissue were then placed in a preserving solution, and
3 slices from each rat were selected to be stained and examined further for c-Fos content.
A separate set of sections was selected to be stained for BrdU incorporation. The
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sections of tissue were chosen based on their representation of the dentate gyrus. A rat
brain atlas was utilized to determine which sections of the brain tissue were to be
examined (Paxinos & Watson, 1998). One rostral (AP –3.30 mm in reference to
Bregma), middle (AP –2.12 mm in reference to Bregma) and caudal (AP –3.6 mm in
reference to Bregma) section was taken for each rat to represent different sections of the
hippocampus (Paxinos & Watson, 1998).
c-Fos Immunohistochemistry
The c-Fos staining procedure involved washing the selected pieces of tissue for 30
minutes and the placing them in a solution containing the 10 antibody (rabbit anti-Fos
polyclonal IgG, Santa Cruz Lot #c270) that binds to segments of the c-Fos protein. The
concentration was 1:8000, diluted in 50 ml of blocking solution (98.75mL 0.01 M PBS, 1
ml normal goat serum, 1 g bovine serum albumin, 0.25 ml 30% Triton X100). They were
left in this solution overnight, and then rinsed and placed in a solution containing
biotinylated 20 antibodies (goat anti-rabbit polyclonal IgG, Jackson Laboratories) that
recognize the 10 antibody. This concentration was 1:200 diluted in 50 ml of blocking
solution. Two hours later the tissue was rinsed again and avidin-biotin molecules
complexed with horseradish peroxidase diluted in 50 ml of 0.01 M PBS were added.
These molecules bind to the biotin molecules on the antibodies. After one hour enhanced
DAB (Diaminobenzidine enhanced with nickel and cobalt) diluted in 50 ml of 0.1 M PB
was added, which interacted with the peroxidase to form a precipitate that allows for the
visualization of the c-Fos location.
After being left to dry overnight, the slides were coverslipped and viewed under a
microscope. A 240 x 152 µm portion of the dentate gyrus was viewed in each section of
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tissue for each rat. The dimensions of this area were kept constant across rats. For the
middle and caudal sections, the portion of the dentate gyrus that was measured for c-Fos
content was the hilus. For the rostral sections, the lower portion of the dentate gyrus was
measured, and this location was kept constant across caudal sections. Only the darkest
particles in each section were counted, ensuring that only Fos-positive nuclei were being
measured.
BrdU Immunohistochemistry
The BrdU staining procedure was performed as outlined in the kit from Chemicon
International. The procedure first involved the deparaffinization of the control tissue
included with the kit. This involved soaking the paraffinated slides in xylene, and then
washing them in 100%, 90%, 80%, and 70% ethyl alcohol for 3 minutes each.
Afterwards tissue was washed in PBS for 3 minutes. Control slides and experimental
slides were soaked in Quenching Solution (dilute 30% hydrogen peroxide 1:10 in
methanol) for 10 minutes, and then washed with PBS for 2 minutes. Two drops of 0.2%
Trypsin Solution were added to control slides and slides were incubated at room
temperature for 10 minutes. Slides were then washed for 3 minutes in distilled water.
Denaturing Solution was added to all slides and they were allowed to incubate at room
temperature for 30 minutes, followed by 2 PBS washes for 2 minutes each. Blocking
solution was then added to each slide, and they incubated for 10 minutes. Slides were
blotted dry on a paper towel before the Detector Antibody was added, and then were left
to incubate for 60 minutes. Following incubation slides were washed twice with PBS, 2
minutes per wash.
Streptavidin-HRP Conjugate was then added to each slide and slides were
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incubated at room temperature for 10 minutes. This was followed by two 2-minute
washes in PBS. DAB concentrate was added to slides at a concentration of 1 µl for every
29 µl of Substrate Reaction Buffer. Slides were allowed to incubate for 10 minutes and
were washed with distilled water for 2 minutes. Hematoxylin Counterstain was added to
all slides and left to incubate for less than a minute. Slides were briefly washed with
distilled water and then incubated in PBS for 1 minute until the color turned blue. Slides
were washed for 2 minutes in distilled water. To prepare for coverslipping, slides were
incubated in 90% ethanol for 30 seconds, 100% ethanol for 30 seconds, and xylene for 30
seconds. Slides were coverslipped and left to dry overnight.
Results
Weight/activity level analysis
Weights and activity levels were monitored throughout the study to determine if
the administration of chronic nicotine led to significant weight loss or increased
locomotion. One-way ANOVAs were conducted for the weights of the dual-phase cohort
after they had been exposed to nicotine or saline for 14 days in Phase 1 and in Phase 2.
The results for these rats were not significant, indicating that after 14 days of nicotine
administration in both phases, no significant differences arose between the weights of the
saline and nicotine rats. The single-phase cohort also did not demonstrate significant
differences between the weights of rats receiving nicotine and rats receiving saline.
One-way ANOVAs were also conducted for the activity levels of the dual-phase
cohort (in Phases 1 and 2) and the single-phase cohort after they received nicotine or
saline for 14 days to view potential increases in locomotion as a result of nicotine
administration. No significant results were found between the activity levels of the
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nicotine or saline rats in any cohort. This shows that the nicotine did not have a
significant effect on the locomotion of the rats during the experiment.
Spatial learning analysis
Single-phase cohort
A repeated measures analysis using a 2 (group) x 5 (days) mixed design ANOVA
was conducted with trial totals across the 5 days of acquisition. Trial totals were
calculated by adding the latencies of trials 1 through 5 for each rat in each day. The
independent variable was the drug condition and the dependent variables were the trial
latencies.
The effect of condition across days using trial totals was not significant,
indicating that condition had no significant effect on trial totals across days 1 through 5.
However, an effect of training could be found by comparing the trial latencies across
days for all rats, regardless of drug condition. In the analysis of trial totals, a significant
effect of training was seen across the days of the acquisition period, F(4, 52) = 21.49, p <
.001. This shows that the rats learned the task due to an overall decrease in trial latencies.
Performance between groups on each acquisition day was assessed using a 2
(group) x 5 (trials) mixed design analysis of variance (ANOVA), which was conducted
with repeated measures across the 5 trials per day. The effect of condition (nicotine or
saline) on trial latencies for each individual day was not significant, indicating no
significant difference between rats treated with nicotine and rats treated with saline. In
the analyses of individual days, however, a significant effect of training was found for
acquisition days 1 (F(4, 52) = 4.18, p = .005), and 3 (F(4, 52) = 3.18, p = .02), and effects
for days 2, 4, and 5 were not significant (see Figure 2 for a graph of mean trial latencies
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in acquisition days 1-5 that demonstrate the learning of the task). This indicates that the
majority of learning occurred across trials on days 1 and 3, during the earlier days of
acquisition.
A one-way ANOVA was conducted for test trial totals (the sum of all test trials
for each rat), and a separate ANOVA was conducted for test trial averages (the sum of all
test trials for each rat divided by the number of trials). The effect of condition for the
trial totals and averages were not significant, however the means for saline (M = 30.02)
and nicotine (M = 26.52) rats indicate a trend toward significance (see Figure 3 for a
graph of test trial averages at each start location). Additionally, five one-way ANOVAs
were conducted for each test trial (each test trial was at a different start location, and
there were 5 in total) in order to view possible effects of condition. Effects of condition
for test trials 1 through 5 were not significant, indicating that the nicotine did not produce
a significant decrease in trial latencies in adolescent rats.
Dual-phase cohort
Phase 1
Statistical analyses for Phase 1 acquisition were conducted using the same
procedure as outlined for the single-phase cohort. A repeated measures analysis using a 2
(group) x 5 (days) mixed design ANOVA was conducted with trial totals across the 5
days of acquisition. Trial totals were calculated by adding the latencies of trials 1
through 5 for each rat in each day. Again, the independent variable was the drug
condition and the dependent variables were the trial latencies.
The results for this group of adolescent rats in acquisition coincided with those of
the single-phase cohort adolescent rats. The effect of condition across days using trial

Effects of Nicotine 42
totals was not significant, confirming that nicotine did not have a significant effect on
trial totals across acquisition days 1 through 5. The effect of training for trial totals
across days 1 through 5 was significant, F(4, 116) = 57.54, p < .001, indicating learning
due to a decrease in latency totals across acquisition days in Phase 1 acquisition.
Performance between groups on each acquisition day was assessed using a 2
(group) x 5 (trials) mixed design ANOVA, which was conducted with repeated measures
across the 5 trials per day. The effect of condition (nicotine or saline) on trial latencies
for individual days 1, 2, 4, and 5 were not significant, indicating the nicotine did not have
a significant effect in the adolescent rats in Phase 1 of acquisition. There was a
significant effect of condition seen for Day 3, however, indicating a decrease in trial
latencies in the nicotine treated rats, F(4, 116) = 2.56, p = .04. Additionally, there was a
significant effect of training in day 1, F(4, 116) = 7.22, p < .001, and day 2, F(4, 116) =
2.95, p = .02, indicating learning via a decrease in latencies across trials in both
conditions. The effects of training on days 3, 4, and 5 were not significant, coinciding
with the results from the single-phase cohort suggesting that the bulk of learning occurs
during the early days of acquisition (see Figure 4 for a graph of mean trial latencies in
Phase 1 acquisition days 1-5).
A one-way ANOVA was conducted for test trial totals, and a separate ANOVA
was conducted for test trial averages. Effects for trial totals and averages were not
significant, however the averages for trial totals in the saline (M = 26.42) and nicotine (M
= 21.31) conditions indicate a clear trend toward significance (see Figure 5 for a graph of
Phase 1 test trial averages). Additionally, as in the single-phase cohort, five one-way
ANOVAs were conducted for each test trial in Phase 1. Effects of condition for trials 1
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through 5 were not significant, indicating that the nicotine did not produce a significant
difference in latencies in each trial.
Phase 2
Statistical analyses for Phase 2 acquisition were conducted in the same fashion as
in Phase 1 and the single-phase cohort. A repeated measures analysis using a 2 (group) x
5 (days) mixed design ANOVA was conducted with trial totals across the 5 days of
acquisition. Trial totals were calculated by adding the latencies of trials 1 through 5 for
each rat in each day. The independent variable was condition and the dependent
variables were the trial latencies.
In the analysis of trial totals, an effect of condition across days was not seen,
indicating that nicotine did not have a significant effect on trial totals across acquisition
days 1 through 5. A significant effect of training was seen for trial totals across days,
F(4, 116) = 9.86, p < .001. This demonstrates an effect of the task, as latencies in both
conditions decreased as a result of training.
The performance between groups on each acquisition day was assessed using a 2
(group) x 5 (trials) mixed design ANOVA, which was conducted with repeated measures
across the 5 trials per day. An effect of condition (nicotine or saline) for individual days
1 through 5 was not seen, indicating that in the second phase of acquisition, condition did
not have a significant effect on trial latencies. The effects of training for day 1, F(4, 116)
= 8.86, p < .001, and day 2, F(4, 116) = 4.82, p < .001, were significant, indicating a
decrease in latencies due to learning of the task (see Figure 6 for a graph of Phase 2
acquisition trials as compared to Phase 1 acquisition trials). The effects of training for
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days 3, 4, and 5 were not significant, indicating again that the bulk of learning occurred
in the early days of acquisition.
A paired samples t-test was conducted to determine differences between the first
trial in Phase 1 acquisition and the first trial in Phase 2 acquisition. This provided insight
as to whether previous training had a significant effect on trial latencies in Phase 2
acquisition, regardless of group. The difference between the two trials was significant,
t(1, 30) = 9.39, p < .001, indicating that trial latencies were significantly decreased in
Phase 2 acquisition when compared to Phase 1 (this result is also demonstrated in the
graphs in Figure 6).

For Phase 2 acquisition, a one-way ANOVA was also conducted to

view possible differences in trial latencies across the four drug treatment groups, N/N,
N/S, S/N, or S/S. The independent variable was the drug treatment group and the
dependent variables were the trial latencies. Effects of group for days 1 through 5 were
not significant, indicating no significant differences between groups in the Phase 2
acquisition trials.
Similar to the test trial analyses conducted in the single-phase cohort and Phase 1,
a one-way ANOVA was conducted for test trial totals, and a separate ANOVA was
conducted for test trial averages. The independent variable was condition (rats that
received either nicotine or saline in Phase 2), and the dependent variables were trial
latencies. The effect of condition on trial totals was significant, F(1, 29) = 9.16, p = .005,
demonstrating that the nicotine treated adult rats had lower overall trial latencies
compared to saline treated rats. A significant effect of condition was also seen in trial
averages, indicating lower trial latency averages in nicotine rats than in saline rats, F(1,
29) = 9.16, p = .005 (see Figure 7 for a graph of Phase 2 test trial averages). This shows
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that the nicotine rats demonstrated increased learning of the task when compared to saline
rats.
Additionally, five one-way ANOVAs were conducted for each test trial in Phase
2, with condition (nicotine or saline) as the independent variable and trial latencies as the
dependent variable. Significant effects of condition were found for trial 1, which had the
same start location as the acquisition trials, F(1, 29) = 6.19, p = .019, trial 4, F(1, 29) =
6.59, p = .016, and for trial 2, F(1, 29) = 4.12, p = .05. This indicates that in these testing
trials, the nicotine had a positive effect on the cognition of the older rats. The effects in
trials 3 and 5 were not significant. These results, coupled with the results from the test
trial totals and test trial averages, demonstrate that nicotine administration led to lower
trial latencies in adult rats.
A one-way ANOVA and LSD follow-up tests were then conducted to view
differences between the four drug treatment groups, N/N, N/S, S/N, and S/S, in the Phase
2 test trials. The independent variables were the four groups with varying drug
conditions, and the dependent variables were the trial latencies. Trial totals for each
group were calculated, and these scores were used in the ANOVA. A significant effect
of group was found for trial totals, F(3, 27) = 3.03, p = .047. Least Square Difference
(LSD) post-hoc tests conducted at a significance level of p < .05 confirmed that groups
receiving nicotine responded more quickly in the MWM due to decreased trial latencies.
LSD tests indicated that for trial totals, the N/N group was significantly faster than the
N/S group (mean difference = 8.57) and the S/N group was significantly faster than the
N/S group (mean difference = 9.31).
Five one-way ANOVAs were conducted using the four groups as the independent
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variables and the test trial latencies as the dependent variables, in order to view
differences between groups in individual trials. The effects of the groups in individual
trials 1 through 5 were not significant. However, LSD tests indicated a significant
difference between the N/N group and S/S group in Trial 1 (mean difference = .81) and
Trial 4 (mean difference = 2.08), as shown in Figure 8. Though the effects of these were
not significant in the ANOVA, the significant post-hoc test provides more support for the
result that nicotine rats in Phase 2 were faster than saline rats. For a graph demonstrating
the differences between the N/N, N/S, S/N, and S/S test trial averages, see Figure 9.
A one-way ANOVA was conducted for Phase Differences, which was the
difference in latencies for the four groups (N/N, N/S, S/N, S/S) between Phase 1 and
Phase 2. A near-significant effect of condition was found, F(3, 27) = 2.93, p = .051, and
no significant effect was seen for age alone. This indicates an effect of the nicotine as the
rats aged, however the lack of a significant result for age alone suggests that due to the
previous training, there was no significant difference between test trial latencies in Phase
2 versus Phase 1. LSD post-hoc tests indicated a significant difference between the S/N
and N/S groups, showing that the rats receiving saline in Phase 1 and nicotine in Phase 2
(S/N) had significantly lower trial latencies than rats receiving nicotine in Phase 1 and
saline in Phase 2 (N/S) (mean difference = 16.36).
c-Fos Analysis
Separate one-way ANOVAs were conducted for Phase 2 of the dual-phase cohort
and the single-phase cohort to analyze c-Fos expression in the dentate gyrus of the
hippocampus. Here, the independent variables were the drug conditions and brain
sections, while the dependent variable was c-Fos content.
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For Phase 2, three one-way ANOVAs were conducted across condition (nicotine
or saline) on c-Fos expression separately for each section of the hippocampus. The three
sections of interest were the rostral, middle, and caudal portions of the dentate gyrus. A
significant effect of condition was seen in the caudal section, F(1, 26) = 10.43, p = .003.
Means indicate that the rats receiving saline in Phase 2 (M = 14.47) had higher c-Fos
content in this section than did the rats receiving nicotine in Phase 2 (M = 9.23). Effects
for the rostral and middle sections were not significant, indicating the largest c-Fos
difference occurred in the caudal hippocampus section. See Figures 10, 11, and 12 for
examples of rostral, middle, and caudal sections of the dentate gyrus for both saline and
nicotine rats. A one-way ANOVA conducted for the single-phase cohort revealed no
significant effect of condition across nicotine and saline rats in any brain section,
indicating that the nicotine did not have an effect on c-Fos content in the adolescent rats.
Three one-way ANOVAs and LSD post hoc tests at significance level p < .05
were also conducted in Phase 2 to view differences between the N/N, N/S, S/N, and S/S
groups in the three hippocampus sections. Here, the independent variables were the four
groups, and the dependent variable was the c-Fos content. Again, the effect of group for
the caudal section was significant, F(3, 24) = 4.14, p = .017, indicating significantly
higher c-Fos expression in the saline rats. LSD post-hoc tests indicated that S/S rats had
significantly more c-Fos than N/N rats (mean difference = 6.08), and than S/N rats (mean
difference = 7.00). No significant effects of group were seen for the rostral and middle
sections.
To view differences relating to age between the Phase 2 rats and the single-phase
cohort, three 2 (age) x 2 (condition) ANOVAs were conducted for the three hippocampus

Effects of Nicotine 48
sections of interest. Phase 2 rats were considered adults and single-phase cohort rats
were adolescents, and they compared by condition (nicotine or saline). Again, a
significant effect of condition was seen in the caudal section of the hippocampus, F(1,
37) = 8.22, p = .007, indicating the saline rats showed more c-Fos expression than the
nicotine rats. Significant effects for age were seen in the rostral section, F(1, 37) = 5.34,
p = .027, and the caudal section, F(1, 37) = 5.78, p = .021, indicating that adolescent rats
showed less c-Fos expression than adult rats. The effect of age in the middle section
indicated a trend toward significance, F(1, 37) = 3.52, p = .069.
BrdU Analysis
No BrdU expression was demonstrated in the dentate gyrus of the hippocampus in
the rostral, middle, and caudal sections examined for the single-phase and dual-phase
cohorts.
Discussion
The hypothesis that rats receiving nicotine would be significantly improved in the
test trials of the Morris water maze task when compared to rats receiving saline was
partially supported: The adult rats demonstrated a clear improvement in the task after
nicotine exposure, while the adolescent rats did not demonstrate such improvement. As
expected, in Phase 2 testing the N/N rats were significantly improved at the task when
compared to the three other groups, and the S/N rats were improved compared to the S/S
and N/S groups that received saline in Phase 2. The hypothesis that previous training in
the Morris water maze would lead to lower trial latencies overall in Phase 2 of acquisition
was supported, as all rats (regardless of drug condition) demonstrated much faster
reaction times than they did in Phase 1. However, the hypothesis that nicotine rats in
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Phase 2 of acquisition would re-acquire the task faster than the saline rats was not
supported, indicating that the nicotine did not have an effect on the re-acquisition of the
task from the same start location.
The hypothesis regarding c-Fos in the dentate gyrus of the hippocampus was not
supported, as we expected to see an increase in c-Fos in the nicotine rats. There was,
however, a significant increase in c-Fos in the dentate gyrus of the rats that received
saline in Phase 2, as the S/S group had a much higher amount of c-Fos than the N/N and
S/N groups. Additionally, it was found that adult rats demonstrated more c-Fos
expression in the hippocampus than adolescents from the single-phase cohort. The
hypothesis that there would be an increase in BrdU in the dentate gyrus of the nicotine
rats was not supported, as we were not able to obtain any BrdU expression in our tissue.
This could have been due to a number of methodological factors, which will be expanded
upon later.
Behavioral Effects of Nicotine
In adolescent rats, contrary to our original hypothesis, there were no significant
differences between the nicotine and saline rats. These rats were approximately two
months old, and still at an early stage of development. It is possible that the lack of a
significant difference in the acquisition and test trials for the adolescent rats (in both the
single-phase cohort and Phase 1 of the dual-phase cohort) is due to the fact that a nicotine
dose of 0.2 mg/kg/day is not enough to demonstrate such an effect in rats of this age. It
has already been demonstrated that adolescent rats metabolize drugs faster than adult rats,
so it is possible that in order to see a change in trial latencies, adolescent rats would need
to be administered a higher dose of nicotine (French et al., 2006). This conclusion
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coincides with a previous study that gave adolescent and aged rats a high nicotine dose of
0.5 mg/kg/day, but demonstrated an improvement in the working memory of the
adolescent rats only (Levin & Torry, 1996). This provides evidence for a possible dosing
threshold in both adolescents and adult rats.
In Phase 2 of testing, when the rats in the dual-phase cohort were approximately 6
months old and thus considered adults, complete support of our hypothesis was
demonstrated. The results from the test trials for this phase, in which rats were to find the
hidden platform from varying start locations, demonstrated a clear decrease in trial
latencies in the nicotine rats as compared to the saline rats. This follows from studies that
have demonstrated nicotine as having a pronounced effect on aged rats (French et al.,
2006; Socci et al., 1995). Additionally, previous studies have demonstrated the
importance of allowing a few days for the drug to take effect before starting acquisition
trials (Bernal et al., 1999). Because the rats in this study were given a week prior to
acquisition to acclimate to the drug, it can be concluded that the effects of the nicotine in
the Morris water maze in Phase 2 of testing were due to the nicotine itself and not some
other factor. It can also be concluded that the improvement in the Morris water maze
task among adult rats receiving nicotine was not due to an increase in locomotion as a
result of the nicotine, as the results demonstrate that nicotine did not have an effect on the
activity levels of the rats. This provides more evidence that the nicotine served to
increase the cognition of the rats, and not merely to increase their locomotion.
Our study is unique in that the rats in the dual-phase cohort were given varying
drug schedules that allowed for four separate groups to be examined—this allows us to
draw conclusions regarding the level of impact the nicotine has on the rats’ ability to
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learn the Morris water maze task. In Phase 2, our hypothesis was supported because we
found that the N/N rats had significantly lower latencies in the test trials than the N/S rats
and the S/S rats. This provides evidence that learning in the Morris water maze was
state-dependent on the nicotine—when rats received nicotine in Phase 1 and then nicotine
again in Phase 2, they performed very well in the test trials in Phase 2. When rats
received nicotine in Phase 1 and saline in Phase 2, they demonstrated impairment when
compared to all other rats (including the S/S group). This suggests that when rats are
deprived of nicotine and then faced with a task they learned while under the influence of
nicotine, the absence of nicotine leads them to perform worse on the task than they would
have if they had never received nicotine in the first place. In Phase 2 of this study,
however, the rats were faced with the same exact task under identical conditions. It is
possible that if faced with a slightly different task, or the same task in a different
environment, the deficits would not be as pronounced. Thus, the extent to which learning
is state-dependent on nicotine is an area that lends itself to further study.
These results also demonstrate the importance of previous training in conjunction
with the drug treatment, as the re-acquisition of the task in Phase 2 demonstrated lower
latencies overall than did the acquisition in Phase 1. Clearly the previous training helped
the animals learn the task, most likely due to Long Term Potentiation (LTP) in the
hippocampus. Because the training led to an increase in neuronal firing and expression,
the rats were able to perform better during the second phase of acquisition. This follows
from previous research that highlights early training as an indicator of long-term
memory—because the rats remembered the task from the previous acquisition phase, they
were able to re-acquire it much more quickly in Phase 2 (Hansalik et al., 2006).
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Because the nicotine did not produce a significant difference in acquisition trials
in Phase 2, it can also be concluded that the previous training in the maze from that start
location is what allowed the rats to recall the task much more quickly than they did in
Phase 1. Additionally, the test trial latencies in Phase 2 did not differ overall from test
trial latencies in Phase 1—thus, the main difference in latencies from one phase to the
next was seen in the acquisition trials. The real difference between nicotine and saline
rats was seen in the Phase 2 test trials, in which the rats had to remember the task relying
only on spatial cues. In this instance, it is clear that the nicotine improved the spatial
learning and memory retention in the rats.
Neuronal Effects of Nicotine
Initially, we hypothesized that there would be an increase in c-Fos expression in
the adult rats in Phase 2 as a result of the nicotine expression. Though this hypothesis
was not supported, a significant result in the opposite direction was found. The saline
rats in Phase 2 demonstrated an increase in c-Fos in the dentate gyrus of the hippocampus
when compared to nicotine rats. Though this did not follow with our hypothesis
regarding c-Fos as an indicator of neuronal change, it follows from previous research
investigating c-Fos as an indicator of stress (Kovacs, 1998). Previous research
demonstrating an increase in c-Fos as a result of nicotine exposure has shown that higher
doses (of up to 2 mg/kg) of nicotine lead to this expression (McCormick & Ibrahim,
2007; Ren & Sagar, 1992). Because the dose used in the present study was quite low (0.2
mg/kg), it is possible that this was not enough nicotine to produce a c-Fos increase in the
nicotine rats. That being said, the increase in c-Fos in saline rats could instead be due to
the increased amount of stress the saline rats were under. Because the results show that
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saline rats demonstrated significantly higher latencies in the test trials of the MWM task,
it is possible that being in the maze for a longer period of time led to more stress in these
rats when compared to the nicotine rats that were in the maze for much shorter periods of
time. This follows from studies examining the effects of swim stress on rats—rats forced
to swim (usually for 15 minutes) with no escape platform show high stress levels as
indicated by increased c-Fos expression in the brain (Lino-de-Oliveira et al., 2006).
Though it seems this will often be a confound in an experiment like this, it would
be possible to use a different Morris water maze method that would eliminate the
possibility of increased stress in the rats with higher trial latencies. In this experiment,
the platform was present at all times during the test trials. A future experiment could
employ the use of a camera suspended over the maze during test trials—the platform
would be removed, and the amount of time the rats spend in each quadrant would be
assessed instead. The amount of time spent in the quadrant that contained the platform
during acquisition would be the measure of spatial learning. This way, all rats would be
in the maze for the same amount of time (generally 60 seconds), and increased stress as a
result of higher swimming times would not potentially skew the c-Fos results.
Though we expected to see an increase in cell proliferation in the dentate gyrus of
the hippocampus as evidenced by BrdU, no such staining was obtained. Due to a number
of studies demonstrating an increase in neurogenesis in the hippocampus as evidenced by
BrdU expression after nicotine administration and spatial learning, the lack of BrdU
staining is most likely because of a problem with our procedure (Dalla et al., 2007;
Dobrossy et al., 2003). It is possible that the number of injections was not enough to lead
to significant BrdU staining in the hippocampus. Previous studies employing the use of
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BrdU generally use three or more injections of 50 mg/kg BrdU, or they use one or two
injections of an extremely high concentration of BrdU (Dalla et al., 2007; He & Crews,
2007; Scerri et al., 2006). In this study, we only injected the rats twice with a
concentration of 50 mg/kg BrdU, and it is possible that in order for the nicotine or
training to have an impact on BrdU expression we would have needed more injections.
In addition to administering more BrdU injections, it would be beneficial in the
future to modify the injection schedule so the timing coincides with the time when the
most learning takes place. A previous study divided the learning process in the Morris
water maze into an early phase, in which most of the learning occurs, and a late phase, in
which the latencies decrease and level off (Dobrossy et al., 2003). It was found in the
study that the early phase of learning did not produce significant cell proliferation
potentially due to increased stress of a new task, but that the late phase of learning did
demonstrate increased cell proliferation as evidenced by BrdU (Dobrossy et al., 2003).
However, the study employed fewer acquisition trials per day, and they only looked at
acquisition (what they termed “learning”) trials. The timing of our injections was right
before the last day of acquisition and before the first day of testing—it is possible that
because at this point the rats had already significantly learned the task, there were not
enough newly-formed cells to demonstrate BrdU incorporation in the hippocampus. It
can also be argued that the later acquisition trials in our study were less hippocampaldependent because the rats had already been exposed to a number of trials from the same
start location. If this is the case, it makes sense that there was no BrdU expression in the
hippocampus after these trials. Instead, administering injections during the first
acquisition days in which the bulk of the learning occurs would most likely lead to an
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increase in BrdU expression.
Due to our knowledge of the effects of nicotine at the neural level, it can be
concluded that despite the lack of c-Fos and BrdU expression in the nicotine rats, the
nicotine still had an effect on the nAChRs in the rats’ brains. The hippocampus is known
to be highly involved in memory and learning due to LTP, which is an increase in
synaptic effectiveness. Because the behavioral data demonstrated that the adult rats
treated with nicotine were significantly improved in the Phase 2 test trials, we can reach
the conclusion that the nicotine was binding to nAChRs and stimulating the release of
neurotransmitters in the brain. This led to an increase in neuronal firing, as indicated by
the enhancement in their cognition as related to the Morris water maze task.
The results of this study follow from previous studies investigating the effects
nicotine has on the hippocampus. It has been shown that nicotine facilitates synaptic
activity and can increase LTP in the hippocampus via tasks involving memory and
learning (Rezvani & Levin, 2001). Nicotine’s positive effect on LTP has also been
supported by studies investigating nicotine as a neuroprotective agent in rats that have
been exposed to significant stressors (Aleisa et al., 2006). In the case of Alesia and
colleagues (2006), nicotine was shown to normalize LTP and counteract working
memory impairments that were induced by stress. Nicotine has also been shown to
attenuate working memory deficits as induced by certain drugs, again providing evidence
that nicotine is neuroprotective and plays a significant role in LTP in the hippocampus
(Levin, Bettegowda et al., 1998).
While there is significant evidence that nicotine leads to increased neuronal firing
and LTP in the hippocampus as a result of tasks involving memory and learning, it is

Effects of Nicotine 56
possible that the site of neuronal change could be elsewhere in the brain, or in addition to
these hippocampal effects. Studies have shown that nAChRs are also present in other
brain areas, such as the amygdala, the prefrontal cortex, the thalamus, and the motor
cortex (Levin, McClernon et al., 2006; Mansvelder et al., 2006). It would be beneficial
to investigate these brain areas with respect to nicotine exposure and working memory
tasks, as this would provide a more complete view of the neural mechanisms of nicotine.
Limitations
The limitations of this study mostly involved the newness of the procedure. The
osmotic mini pumps had never been used in this laboratory before, and due to some
complications in the first round of surgeries a few rats lost their pumps. This was most
likely due to poor placement of the pumps, as the first batch had the releasing end of the
pump facing the wound. The excessive scratching that led to the loss of the pumps could
have been due to the nicotine aggravating the wounds before they healed. After the first
round of surgeries all other surgeries were completed without incident, providing further
evidence that the pump placement was the reason for the excessive scratching and
subsequent pump loss.
The use of BrdU was another limitation in this study. It did not immediately go
into solution, so based on the findings of previous studies we heated the BrdU
significantly in order to help it dissolve (Hume & Keat, 1990). We later found, however,
that heating BrdU might actually decrease the likelihood that it will incorporate into new
neurons. Despite this, the previous literature that used the heating technique did still see
BrdU expression—thus, it was most likely a problem with the timing of our injections
that led to the lack of expression (Hume & Keat, 1990). The results from the present

Effects of Nicotine 57
study suggest that the ideal time to inject BrdU is when learning is most evident, which
would have been during days 1 and 2 of the acquisition trials.
Another potential limitation in this study could have been in the use of the Morris
water maze. There are a few different ways the Morris water maze can be used to
demonstrate spatial learning, and the procedure used in this study may be unusual
compared to other, more widely used procedures. Because the rats were to be exposed to
the maze four months after Phase 1 of testing, we wanted to ensure that the rats learned
the task as well as possible during Phase 1. For this reason, we chose to have five days of
acquisition, with five trials from the same start location each day. As the results indicate,
the rats learned the spatial cues by the end of acquisition trials in both Phase 1 and 2. It
can be argued that by the end of the acquisition trials the task was no longer
hippocampal-dependent because the start location remained the same; however the good
performance of the rats in the test trials indicates that the hippocampus was still highly
involved in the task.
There have been previous studies using the Morris water maze as both a
hippocampal-dependent and independent task. It has been found that when the task
involves spatial learning, such as in a traditional Morris water maze study in which rats
must locate a hidden platform, it is dependent upon the hippocampus (Teather, Packard,
Smith, Ellis-Behnke, & Bazan, 2005). This has been evidenced by an increase in c-Fos
in this brain area after such a task (Teather et al., 2005). When a task is due to a
stimulus-response “habit,” such as in a Morris water maze task in which the platform is
visible, the task can be completed independent of the hippocampus, with more reliance
on the dorsal striatum. In the case of habitual learning, the increase in c-Fos is seen in the
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dorsal striatum, and not the hippocampus (Teather et al., 2005). Based on the findings of
this study, it is possible that the later acquisition trials in the present study were more
habitual, and that they relied on the dorsal striatum more than the hippocampus. Yet
these findings still provide support for the test trials as being hippocampal-dependent
because the rats had to find the hidden platform from unfamiliar start locations around the
maze.
Many Morris water maze studies also employ the use of a video camera in order
to assess the amount of time rats spend in each quadrant when the platform is removed
(Bernal et al., 1999; Socci et al., 1995). Because this kind of technology was not
available to our laboratory at the time of Phase 1 acquisition and testing, we chose to
keep the platform in the maze for all parts of the experiment. Therefore, it was necessary
to have all acquisition trials begin at the same start location, and to test the learning of the
task using 5 different start locations around the maze. Although this is a more traditional
method of assessing Morris water maze spatial learning, it still yielded significant results
and demonstrated that, after 5 days of acquisition and 1 test day at varying start locations,
rats learned the task as evidenced by a significant decrease in trial latencies (Morris,
1984).
This study may have also been limited by low statistical power. Though it began
with 50 subjects and an even number of nicotine and saline rats in each group,
complications with the surgeries and pumps caused these numbers to decrease, and
ultimately the data from four subjects were lost before the close of the experiment.
Though the results from the test trials were significant, it is possible that any differences
in the adolescent rats in Phase 1 were too subtle to be demonstrated by the small number
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of rats used in each group. Additionally, the complicated nature of the study design led
us to perform many statistical analyses, which could have contributed to the possibility of
Type I error. Despite this, the conclusions made were based largely on the results of tests
using trial totals and averages, and the separate ANOVAs conducted were simply to view
potential differences within the days of acquisition, and within the individual test trials.
It may be necessary in the future, however, to alter the experimental design to allow for
fewer statistical analyses to avoid this potential problem.
Implications
The results of this study lead to a number of implications that can be translated to
human studies of nicotine’s cognitive-enhancing properties. The finding most relevant to
human research is that nicotine did enhance the cognition of the adult rats. This
conclusion provides continuing support the use of nicotine as a therapeutic alternative for
people suffering from diseases affecting cognition, including Alzheimer’s disease. It also
paves the way for future studies in this area that will give us even more information about
the cognitive enhancing properties of nicotine, and how it can be best utilized for
treatment of such disorders.
The fact that we tested adult rats that were 6 months old as opposed to “aged” rats
that were up to 24 months old could be a potential limitation of this study because it
makes it difficult to compare to previous literature. Most studies examining the
differences between young and aged rats use aged rats because it is easier to relate to
human studies of elderly people, particularly ones with age-associated memory
impairments. The fact that we used adult rats, however, is also beneficial because of the
lack of research done on rats of this age group—we were able to demonstrate that adult
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rats benefited from a small amount of nicotine, which provides important results
regarding a potential dosing threshold between adolescent and adult rats. Previous
studies have only been able to demonstrate that adolescent rats need a higher dose than
aged rats—the current study is able to narrow that age gap, and it suggests that there is a
point between the age of 2 months and 6 months where the dose of nicotine can be
decreased dramatically.
This translates to human studies involving nicotine by suggesting that if adults are
facing a disease affecting their cognition, they do not need a dose as high as an
adolescent might need in order to delay the onset of this disease. This could dramatically
decrease the potential dangers of employing the use of nicotine patches in adult patients,
because they would not be exposed to extremely high doses of nicotine that could lead to
adverse side effects or increased likelihood of addiction. Instead, future studies of
nicotine’s use in adults facing cognitive impairments could begin using a relatively low
dose of nicotine—if that does not produce the desired effects, then a higher dose might be
tested. But the fact that the adult rats in this study benefited from the same low dose that
has been shown to improve cognition in aged rats provides evidence that adult humans
may also benefit from the same dose as the elderly (Socci et al., 1995). Human studies of
nicotine employing the use of nicotine patches delivering 0.9 mg/kg per hour (considered
a moderate dose) to patients in their late 70’s have demonstrated a clear improvement on
tasks of cognition (Wilson et al., 1995). Based on the results of the current study, it
would most likely not be necessary to give an adult a higher dose than that in order to
improve cognition.
The results regarding the dose in this study are also important in demonstrating
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that cigarette smoking is not a safe therapy to use for people with diseases affecting
cognition. Though it has been hypothesized that many patients with schizophrenia and
ADHD self-medicate with cigarettes to obtain nicotine, the results of this study imply that
this practice can actually have adverse effects upon the patients due to the very high dose
of nicotine and the other harmful ingredients in cigarettes (Levin, McClernon et al., 2006;
Winger et al., 2004). Cigarette smoking can actually impair cognition because the nonnicotine ingredients can restrict blood flow to the brain and lead to cell death. Also, the
very high amount of nicotine in cigarettes can actually decrease cognition due to receptor
desensitization (Winger et al., 2004). Thus, nicotine should really be administered by
itself and in a low dose to decrease the potential negative side effects of the drug.
It can also be concluded from the current study that the performance of the adult
rats in the Morris water maze was state-dependent on the nicotine. This means that after
being exposed to nicotine in conjunction with the spatial learning task, it was necessary
to provide nicotine to the rats in any future exposures to the same task. This is why the
group that received nicotine in Phase 1 was impaired in Phase 2 when they received
saline—their learning of the task was dependent on the nicotine, and thus their trial
latencies without it were much higher than rats in all other groups. It is possible,
however, that the detriment in the N/S group might not have been evident if they were
exposed to a different task, or the same task under new circumstances. In the current
study, it is not possible to separate the state-dependent effect from the potential long-term
benefits because we used the same spatial learning task to assess memory retention in
both phases.
Despite the current data regarding the state-dependent effects of nicotine, it is not
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likely that nicotine cessation would produce such profound deficits in humans after
learning a task. In a study examining the potential cognitive deficits due to withdrawal
from the nicotine in cigarettes, impairments on tasks of cognition were seen a few hours
following cessation of the drug (Hatsukami et al., 1989). However, it was mentioned that
other studies using similar methods demonstrated that test scores on tasks of cognition
after quitting were higher than scores obtained when the same participants were engaged
in cigarette smoking (Hatsukami et al., 1989). This suggests that the decline in the study
done by Hatsukami and colleagues (1989) may not have been wholly due to the nicotine
cessation, but also due in part to lasting negative effects of the combination of ingredients
in cigarettes. Additionally, the study did not test their participants beyond 24 hours after
quitting—this would be crucial for conclusions that nicotine cessation produces longterm cognitive deficits. Because this was not done, it is not possible to make this kind of
assertion.
In order to further examine whether cognitive tasks are state-dependent on
nicotine in humans, it would be necessary to perform follow-ups to the studies on
nicotine’s effect on human cognition. There have been a number of studies
demonstrating that a chronic (or even acute) dose of nicotine improves memory and
learning in Alzheimer’s patients, however it would be beneficial to re-examine these
patients after a significant period of time with the same tasks to see if the absence of
nicotine has a negative effect on their ability to perform the task (Jones et al., 1992;
Sahakian et al., 1989; Wilson et al., 1995). This would provide more concrete evidence
for the state-dependent effects of nicotine in humans.
The conclusion from the current study that c-Fos was increased in the
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hippocampus potentially due to the elevated stress levels of the saline rats has interesting
implications for human studies. It suggests that humans who are facing the beginning
stages of cognitive decline could be under significantly more stress than people not
undergoing the same decline. Though more research would need to be done in this area,
it can be hypothesized that if humans are given nicotine to enhance their cognition at
these beginning stages, they may be under much less stress because they would not have
the same level of difficulty performing everyday tasks. Additionally, this provides some
evidence that perhaps nicotine has anxiolytic effects. This is a result that would benefit
from further study, because it provides more support for the development of a therapeutic
treatment for such diseases that enhances cognition and delays the onset of marked
cognitive decline.
Future Studies
Because this is a preliminary study, it lends itself to replication on a larger scale.
Increasing the number of subjects in each group would be extremely beneficial, as the
increase in power would potentially demonstrate subtle changes between groups,
particularly in the adolescent rats. There were many trends toward significance, and it is
assumed that with more subjects, there would be more clear indications of significance.
Replicating this study would also be beneficial as many of the problems encountered
would be anticipated and resolved before they occurred. It is now known how to
properly perform the surgeries, so this would not be a complication, and the
administration of BrdU would be handled differently. More injections of BrdU would be
administered, and the timing of these injections would be altered so that the rats would be
injected during the first two acquisition days. These days were when the bulk of the
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learning occurred, so it is most likely that injections during these two days would lead to
an increase in BrdU expression in the hippocampus.
This study also paves the way for further research in this area. We demonstrated
that a nicotine dose of 0.2 mg/kg showed a significant decrease in the trial latencies of
adult rats in the Morris water maze, but this dose did not demonstrate a decrease in
latencies in adolescents. In the future, this experiment could be replicated by giving a
group of adolescent and adult rats a higher dose of nicotine (for example, 0.4 mg/kg), in
order to determine whether this dose improves the performance of the adolescents, and
whether it impairs the performance of the adults.
Because the results regarding c-Fos expression in the dentate gyrus of the
hippocampus were unexpected, further research regarding nicotine’s effect on c-Fos
expression in the rat brain would be beneficial to our understanding of this relationship.
In order to demonstrate whether the increased c-Fos expression was due to the stress of
having higher trial latencies, it would first be useful to look at c-Fos as a result of Morris
water maze training alone—then the results could be separated into rats with longer
latencies and rats with shorter latencies, to see if the rats that spent more time in the maze
had more c-Fos expression. It would also be beneficial to examine c-Fos expression in
the rat hippocampus as a result of nicotine when stress is not a factor. This would simply
involve administering nicotine for a certain length of time and then examining c-Fos
expression in the hippocampus after that time. If there is c-Fos present in the nicotine
rats, it can be concluded that nicotine increases c-Fos expression when stress is not a
factor.
Because the present study examined the hippocampus only, it would certainly be
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beneficial to examine other brain areas that are linked both with memory and learning,
and also with stress. This would be useful to provide conclusions regarding the effects of
the nicotine at the neural level. Because nicotine can lead to increased attention in
humans, it has been proposed that nicotine may also have an effect on the prefrontal,
parietal, and occipital cortex, as well as the amygdala, and the hippocampus (Mansvelder
et al., 2006). Additionally, the thalamus and the motor cortex have also been shown to
demonstrate a high number of nAChRs, which could also have implications regarding
nicotine’s effect on the human as well as the rat brain. Replicating this study and
examining c-Fos or BrdU expression in some of these brain areas could be extremely
beneficial for this field of research, as the largest amount of work has been done with the
hippocampus. Paying closer attention to the brain areas about which less is known
regarding nicotine’s effects could lead to some important conclusions that could be
carried over to human studies of nicotine. Examining nicotine’s effect on the motor
cortex could be particularly interesting when testing rats in motor tasks like the Morris
water maze, because if nicotine stimulates neuronal growth in this brain area it could
have a significant impact on the ease with which the rats acquire the task.
Conclusions
The current study provides support for the use of nicotine as a therapeutic agent in
diseases affecting cognition. Because of nicotine’s direct stimulation of nAChRs in the
human brain, it would be a more effective alternative to the current treatments available
for diseases like Alzheimer’s, which provide minimal symptom relief. Though a
considerable amount of information is known about nicotine’s effects on the
hippocampus, it is important that future studies examine nicotine’s effects on different
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brain areas in order to provide a more comprehensive view of its neural mechanisms.
Once this knowledge is attained, it will hopefully lead the use of nicotine as a therapeutic
drug—this has the potential to dramatically increase the quality of life for people
suffering from diseases affecting their cognition.
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Table 1
_______________________________________________________________________
Drug Treatment Groups
_______________________________________________________________________
Group

Phase 1

Phase 2

Number of Subjects

N/N

Nicotine

Nicotine

7

N/S

Nicotine

Saline

7

S/N

Saline

Nicotine

9

S/S
Saline
Saline
8
_______________________________________________________________________
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Table 2
_______________________________________________________________________
Experiment Schedule
_______________________________________________________________________
Experimental Day

1

2

3

4

5

6

7

8

Phase 1

A

A

A

A

A

-

-

T

Phase 2
(and single-phase
A
A
A
A
A
T
cohort)
_______________________________________________________________________
Note. A = Acquisition day, T = Test day, dash (-) = no trials
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Figure Caption
Figure 1. Morris water maze start locations and platform placement.
Figure 2. Mean trial latencies for single-phase cohort acquisition.
Figure 3. Mean trial latencies for single-phase cohort test trials.
Figure 4. Mean trial latencies for Phase 1 acquisition.
Figure 5. Mean trial latencies for Phase 1 test trials.
Figure 6. Mean trial latencies for Phase 2 acquisition compared to mean trial latencies
for Phase 1 acquisition.
Figure 7. Mean trial latencies for nicotine and saline rats in Phase 2 test trials.
Figure 8. Mean trial latencies for N/N and S/S rats in Phase 2 test trials.
Figure 9. Mean trial latencies for N/N, N/S, S/N, and S/S in Phase 2 test trials.
Figure 10. Photograph of c-Fos expression in saline and nicotine rats in the rostral
section of the dentate gyrus (arrows point to examples of c-Fos particles).
Figure 11. Photograph of c-Fos expression in saline and nicotine rats in the middle
section of the dentate gyrus.
Figure 12. Photograph of c-Fos expression in saline and nicotine rats in the caudal
section of the dentate gyrus.
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Figure 1.
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Figure 2.
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Figure 3.
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Figure 4.

40
35

25
Nicotine

20

Saline

15
10
5
0
T1
T2
T3
T4
T5
T1
T2
T3
T4
T5
T1
T2
T3
T4
T5
T1
T2
T3
T4
T5
T1
T2
T3
T4
T5

Time (s)

30

Day 1

Day 2

Day 3
Acquisition Days

Day 4

Day 5

Effects of Nicotine 85
Figure 5.
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Figure 6.
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Figure 7.
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Figure 8.
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Figure 9.
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Figure 10.
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Figure 11.
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Figure 12.
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